Deltoid injections of risperidone long-acting injectable in patients with schizophrenia

Innovations in Clinical Neuroscience

Volumn 8, Issue 6, 2011, Pages 20-28

  Quiroz, Jorge A ^a   Rusch, Sarah ^b   Thyssen, An ^b   Palumbo, Joseph M ^a   Kushner, Stuart ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Atypical antipsychotic; Deltoid injections; Gluteal injections; Injection site reactions; Risperidone long acting injectable; Safety; Tolerability

Indexed keywords

HALOPERIDOL; LONG ACTING DRUG; RISPERIDONE;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DELTOID MUSCLE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLUTEUS MAXIMUS MUSCLE; HUMAN; INJECTION SITE INDURATION; INJECTION SITE PAIN; INSOMNIA; LARYNX PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; SWELLING; TACHYCARDIA; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION;

EID: 79960780795     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Carpenter WT, Jr., Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry. 1990 Sep;147(9):1138-1148.
2. Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry. 1991;48(4):333-339.
3. Andreasen NC, Carpenter WT, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-449.
4. Kane JM. Schizophrenia. N Engl J Med. 1996;334(1):34-41.
5. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry. 2003;64(11):1308-1315.
6. Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q. 1997;68(4):377-392.
7. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-891.
8. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998;8(1):55-66.
9. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry. 2001;179:300-307.
10. Thyssen A, Rusch S, Herben V, et al. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol. 2010;50(9):1011-1021.
11. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry. 2004;65(8):1084-1089.
12. Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol. 2004;19(4):241-249.
13. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250-1257.
14. Kane JM, Eerdekens M, Lindenmayer J P, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6): 1125-1132.
15. Lindenmayer J P, Jarboe K, Bossie CA, et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol. 2005;20(4):213-221.
16. Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry. 2001;62(11):855-859.
17. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70(1):91-100.
18. Lasser R, Bossie CA, Gharabawi G, et al. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord. 2004;83(2-3):263-275.
19. Hamann GL, Egan TM, Wells BG, Grimmig JE. Injection site reactions after intramuscular administration of haloperidol decanoate 100mg/mL. J Clin Psychiatry. 1990;51(12):502-504.
20. Hay J. Complications at site of injection of depot neuroleptics. BMJ. 1995;311(7002):421.